Item

Survival and toxicity outcomes of somatostatin analogues vs. other systemic therapies as first-line palliative treatment for patients with extrapulmonary G2 well-differentiated neuroendocrine tumours with a Ki-67 index between 10% and 20%

Dawoodji, A.
; 
Nuttall, C.
; 
Eyong, M.
; 
Farrell, K.
; 
Barratt, N.
; 
McConnell, S.
; 
Chakrabarty, B.
; 
Manoharan, P.
; 
Adam, S.
; 
Hubner, R.
... show 2 more
Citations
Altmetric:
Abstract
Authors
Dawoodji, A.
Nuttall, C.
Eyong, M.
Farrell, K.
Barratt, N.
McConnell, S.
Chakrabarty, B.
Manoharan, P.
Adam, S.
Hubner, R.
McNamara, M.
Frizziero, M.
Affiliation
Christie NHS Fdn Trust, Dept Med Oncol, Manchester, England Christie NHS Fdn Trust, Dept Pathol, Manchester, England Christie NHS Fdn Trust, Dept Radiol & Nucl Med, Manchester, England Christie NHS Fdn Trust, Dept Endocrinol, Manchester, England Univ Manchester, Fac Biol Med & Hlth, Div Canc Sci, Manchester, England
Description
Date
2025
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Dawoodji A, Nuttall C, Eyong M, Farrell K, Barratt N, McConnell S, et al. Survival and toxicity outcomes of somatostatin analogues vs. other systemic therapies as first-line palliative treatment for patients with extrapulmonary G2 well-differentiated neuroendocrine tumours with a Ki-67 index between 10% and 20%. Journal of neuroendocrinology. 2025 MAR;37. PubMed PMID: WOS:001535097100185. English.
Journal Title
Journal ISSN
Volume Title
URI
https://christie.openrepository.com/handle/10541/628131
Embedded videos